Article | Published:

Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation

Oncogene (2018) | Download Citation

Abstract

Hepatitis B virus X protein (HBx) contributes to Hepatitis B virus (HBV)-related liver cancer. However, its impact on hepatocyte proliferation and genomic stability remains elusive. We studied the role of HBx expression on the progression of cell cycle and liver polyploidization during proliferation and liver carcinogenesis. Full-length HBx transgenic mice (FL-HBx) were developed to investigate liver ploidy as well as hepatocyte proliferation, along normal liver maturation and during cancer initiation (chemical carcinogen treatment). Investigation of postnatal liver development in FL-HBx showed an aberrant G1/S and G2/M transitions, triggered (1) a delay of the formation of hepatocytes binucleation, (2) the early synthesis of polyploidy nuclei (≥4n) and (3) DNA damage appearance. Moreover, HBV infection during hepatocytes proliferation in a humanized liver mouse model led, to modifications in polyploidy of hepatocytes. In initiation of hepatocellular carcinoma, FL-HBx protein decreased ChK1 phosphorylation, Mre11 and Rad51 expression, upregulated IL-6 expression and impaired apoptosis. This was related to DNA damage accumulation in FL-HBx mice. At day 75 after initiation of hepatocellular carcinoma, FL-HBx mice revealed significant cell cycle changes related to the increased amount of 4n nuclei and of markers of cancer progenitor cells. Finally, PLK1 upregulation and p38/ERK activation in FL-HBx mice were implicated in aberrant polyploidization favoring DNA damage propagation and hepatocyte transformation. In conclusion, our data indicate that FL-HBx protein increases DNA damage through the hijack of hepatocyte polyploidization. That leads to enhancement of hepatocellular carcinoma initiation in an inflammatory context.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84–101.

  2. 2.

    Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:144–52.

  3. 3.

    Bandopadhyay M, Sarkar N, Datta S, Das D, Pal A, Panigrahi R, et al. Hepatitis B virus X protein mediated suppression of miRNA-122 expression enhances hepatoblastoma cell proliferation through cyclin G1-p53 axis. Infect Agent Cancer. 2016;11:40.

  4. 4.

    Qiao L, Leach K, McKinstry R, Gilfor D, Yacoub A, Park JS, et al. Hepatitis B virus X protein increases expression ofp21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology. 2001;34:906–17.

  5. 5.

    Wu BK, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, et al. Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun. 2006;340:916–28.

  6. 6.

    Quetier I, Brezillon N, Duriez M, Massinet H, Giang E, Ahodantin J, et al. Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice. J Hepatol. 2013;59:285–91.

  7. 7.

    Na TY, Ka NL, Rhee H, Kyeong D, Kim MH, Seong JK, et al. Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma. Oncogene. 2016;35:5435–45.

  8. 8.

    Bontron S, Lin-Marq N, Strubin M. Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2. J Biol Chem. 2002;277:38847–54.

  9. 9.

    Qadri I, Fatima K, Abde LHH. Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH. BMC Microbiol. 2011;11:48.

  10. 10.

    Yue D, Zhang Y, Cheng L, Ma J, Xi Y, Yang L, et al. Hepatitis B virus X protein (HBx)-induced abnormalities of nucleic acid metabolism revealed by (1)H-NMR-based metabonomics. Sci Rep. 2016;6:24430.

  11. 11.

    Kim S, Lee HS, Ji JH, Cho MY, Yoo YS, Park YY, et al. Hepatitis B virus X protein activates the ATM-Chk2 pathway and delays cell cycle progression. J Gen Virol. 2015;96:2242–51.

  12. 12.

    Cheng B, Zheng Y, Guo X, Wang Y, Liu C. Hepatitis B viral X protein alters the biological features and expressions of DNA repair enzymes in LO2 cells. Liver Int. 2010;30:319–26.

  13. 13.

    Forgues M, Difilippantonio MJ, Linke SP, Ried T, Nagashima K, Feden J, et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol. 2003;23:5282–92.

  14. 14.

    Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res. 2004;2:159–69.

  15. 15.

    Rakotomalala L, Studach L, Wang WH, Gregori G, Hullinger RL, Andrisani O. Hepatitis B virus X protein increases the Cdt1-to-geminin ratio inducing DNA re-replication and polyploidy. J Biol Chem. 2008;283:28729–40.

  16. 16.

    Studach LL, Rakotomalala L, Wang WH, Hullinger RL, Cairo S, Buendia MA, et al. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. Hepatology. 2009;50:414–23.

  17. 17.

    Gentric G, Desdouets C. Polyploidization in liver tissue. Am J Pathol. 2014;184:322–31.

  18. 18.

    Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB, et al. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature. 2010;467:707–10.

  19. 19.

    Toyoda H, Bregerie O, Vallet A, Nalpas B, Pivert G, Brechot C, et al. Changes to hepatocyte ploidy and binuclearity profiles during human chronic viral hepatitis. Gut. 2005;54:297–302.

  20. 20.

    Guidotti JE, Bregerie O, Robert A, Debey P, Brechot C, Desdouets C. Liver cell polyploidization: a pivotal role for binuclear hepatocytes. J Biol Chem. 2003;278:19095–101.

  21. 21.

    Kudryavtsev BN, Kudryavtseva MV, Sakuta GA, Stein GI. Human hepatocyte polyploidization kinetics in the course of life cycle. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:387–93.

  22. 22.

    Margall-Ducos G, Celton-Morizur S, Couton D, Bregerie O, Desdouets C. Liver tetraploidization is controlled by a new process of incomplete cytokinesis. J Cell Sci. 2007;120:3633–9.

  23. 23.

    Celton-Morizur S, Merlen G, Couton D, Margall-Ducos G, Desdouets C. The insulin/Akt pathway controls a specific cell division program that leads to generation of binucleated tetraploid liver cells in rodents. J Clin Invest. 2009;119:1880–7.

  24. 24.

    Duncan AW, Hanlon Newell AE, Smith L, Wilson EM, Olson SB, Thayer MJ, et al. Frequent aneuploidy among normal human hepatocytes. Gastroenterology. 2012;142:25–8.

  25. 25.

    Pandit SK, Westendorp B, de Bruin A. Physiological significance of polyploidization in mammalian cells. Trends Cell Biol. 2013;23:556–66.

  26. 26.

    Gentric G, Maillet V, Paradis V, Couton D, L’Hermitte A, Panasyuk G, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest. 2015;125:981–92.

  27. 27.

    Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology. 2000;31:1246–50.

  28. 28.

    Quetier I, Brezillon N, Revaud J, Ahodantin J, DaSilva L, Soussan P, et al. C-terminal-truncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis. J Gen Virol. 2015;96:614–25.

  29. 29.

    Schmit TL, Ahmad N. Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther. 2007;6:1920–31.

  30. 30.

    Awad MM, Enslen H, Boylan JM, Davis RJ, Gruppuso PA. Growth regulation via p38 mitogen-activated protein kinase in developing liver. J Biol Chem. 2000;275:38716–21.

  31. 31.

    Kurata S. Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. J Biol Chem. 2000;275:38716–21.

  32. 32.

    Tarn C, Zou L, Hullinger RL, Andrisani OM. Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol. 2002;76:9763–72.

  33. 33.

    He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell. 2013;155:384–96.

  34. 34.

    Pandey V, Kumar V. HBx protein of hepatitis B virus promotes reinitiation of DNA replication by regulating expression and intracellular stability of replication licensing factor CDC6. J Biol Chem. 2012;287:20545–54.

  35. 35.

    Gentric G, Desdouets C. Liver polyploidy: Dr Jekyll or Mr Hide? Oncotarget. 2015;6:8430–1.

  36. 36.

    Tormos AM, Rius-Perez S, Jorques M, Rada P, Ramirez L, Valverde AM, et al. p38alpha regulates actin cytoskeleton and cytokinesis in hepatocytes during development and aging. PLoS ONE. 2017;12:e0171738.

  37. 37.

    Parrilla A, Cirillo L, Thomas Y, Gotta M, Pintard L, Santamaria A. Mitotic entry: The interplay between Cdk1, Plk1 and Bora. Cell Cycle. 2016;15:3177–82.

  38. 38.

    Studach L, Wang WH, Weber G, Tang J, Hullinger RL, Malbrue R, et al. Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy. J Biol Chem. 2010;285:30282–93.

  39. 39.

    Wang SN, Lee KT, Tsai CJ, Chen YJ, Yeh YT. Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest. 2012;42:1295–301.

  40. 40.

    Wang Y, Cui R, Zhang X, Qiao Y, Liu X, Chang Y, et al. SIRT1 increases YAP- and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma. Oncotarget. 2016;7:11284–98.

  41. 41.

    He ZL, Zheng H, Lin H, Miao XY, Zhong DW. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol. 2009;15:4177–82.

  42. 42.

    Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017;32:57–70 e53.

  43. 43.

    Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology. 2012;55:108–20.

  44. 44.

    Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766–70.

  45. 45.

    Brezillon N, Brunelle MN, Massinet H, Giang E, Lamant C, DaSilva L, et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS ONE. 2011;6:e25096.

Download references

Acknowledgements

We thank S. Berissi and N. Gadessaud (Inserm US24/CNRS UMS3633) for tissue processing and slide staining, S. Morosan and O. Bregerie (UMS28, phénotyage du petit animal, UPMC-Paris VI) for animal care.

Funding

This work was supported by grants from the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) (AO 2014-1 16032), Ligue Contre le Cancer (2016, RS16/75-7 and 2017 RS17/75-23), Institut National de la Santé et de la Recherche Médicale (Inserm) and Université Pierre et Marie Curie (UPMC). J.A. was supported by an ANRS doctoral grant.

Author contributions

DK, JA, and CD contributed to conception of the study and design. JA, MB, CC, and JM performed experiments. All authors contributed to the interpretation of results. DK, JA, and CD drafted the manuscript.

Author information

Affiliations

  1. Inserm U1135 CIMI-Paris, Team «Persistent Viral Infections», Paris, France

    • James Ahodantin
    • , Patrick Soussan
    •  & Dina Kremsdorf
  2. Université Pierre et Marie Curie, Paris, France

    • James Ahodantin
    • , Patrick Soussan
    •  & Dina Kremsdorf
  3. CNRS, ERL 8255, Paris, France

    • James Ahodantin
    • , Patrick Soussan
    •  & Dina Kremsdorf
  4. Inserm, U1016, Institut Cochin, Paris, France

    • Myriam Bou-Nader
    •  & Chantal Desdouets
  5. CNRS, UMR8104, Paris, France

    • Myriam Bou-Nader
    •  & Chantal Desdouets
  6. Université Paris Descartes, Sorbonne Paris Cité, Paris, France

    • Myriam Bou-Nader
    •  & Chantal Desdouets
  7. Cytometry Core Facility, Inserm US24/CNRS UMS 3633-SFR Necker, Paris, France

    • Corinne Cordier
    •  & Jérôme Mégret
  8. Faculté de Médecine, Paris Descartes, Paris, France

    • Corinne Cordier
    •  & Jérôme Mégret

Authors

  1. Search for James Ahodantin in:

  2. Search for Myriam Bou-Nader in:

  3. Search for Corinne Cordier in:

  4. Search for Jérôme Mégret in:

  5. Search for Patrick Soussan in:

  6. Search for Chantal Desdouets in:

  7. Search for Dina Kremsdorf in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Dina Kremsdorf.

Suppementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41388-018-0607-3